INTRODUCTION
============

Ligation of the inferior mesenteric artery (IMA) is essential for curative resection of colorectal cancer. Adequate ligation of the IMA ensures en bloc excision of lymph nodes (LN) associated with a tumor \[[@b1-ac-2018-10-09]\]. The ligation techniques routinely used globally are ligation of the IMA at its origin from the aorta (high ligation) or ligation of the IMA below the origin of the left colic artery (low ligation) \[[@b1-ac-2018-10-09], [@b2-ac-2018-10-09]\]. High ligation of the IMA is a universally accepted technique \[[@b2-ac-2018-10-09], [@b3-ac-2018-10-09]\]. However, the appropriate level of IMA ligation remains controversial \[[@b4-ac-2018-10-09]\].

The level of IMA ligation (both, high, and low) is associated with specific advantages and disadvantages. High ligation of the IMA preserves an adequate length of the colon to perform a successful anastomosis \[[@b5-ac-2018-10-09]\]. A few studies have shown that high ligation provides a longer colonic segment than that available with low ligation \[[@b5-ac-2018-10-09], [@b6-ac-2018-10-09]\]. High ligation of the IMA facilitates apical LN dissection \[[@b7-ac-2018-10-09]\]. However, the risk of ischemic colitis or ischemic complications is higher in patients undergoing high ligation of the IMA \[[@b8-ac-2018-10-09]\]. Despite the oncologic advantages of high over low ligation, previous studies have failed to demonstrate better survival rates with the former technique \[[@b1-ac-2018-10-09], [@b7-ac-2018-10-09], [@b9-ac-2018-10-09]\]. Low ligation of the IMA is less invasive and offers the advantage of maintaining adequate anastomotic perfusion \[[@b10-ac-2018-10-09]\].

Oncologic, anatomical, and technical factors determine the level of IMA ligation \[[@b2-ac-2018-10-09]\]. Recently, the occurrence of colorectal cancer has increased in elderly patients, who often present with several comorbidities \[[@b11-ac-2018-10-09]\]. Thus, low ligation of the IMA is preferred in this patient population secondary to the safety and other advantages of the procedure. However, the oncologic benefits of high ligation cannot be ignored. We hypothesized that the oncologic benefit of low ligation of the IMA with additional LN retrieval at its origin is similar to that associated with high ligation. In this study, we aimed to assess the oncologic benefits of low ligation of the IMA with additional LN retrieval at its origin.

METHODS
=======

A retrospective review was performed of a prospectively collected consecutive series between January 2011 and July 2015. All patients underwent curative resection of a primary colorectal tumour. The inclusion criteria were (1) histologically proven adenocarcinoma; (2) tumor location in the sigmoid colon or rectum; and (3) curative resection with IMA ligation. The exclusion criteria were (1) distant metastasis at the time of diagnosis; (2) synchronous colorectal cancer; (3) metachronous colorectal cancer; (4) other malignancy; (5) diagnosis of familial adenomatous polyposis; and (6) a follow-up period less than 24 months. We reviewed the medical records of 1,115 patients. Of them, 507 matched inclusion and exclusion criteria ([Fig. 1](#f1-ac-2018-10-09){ref-type="fig"}). This study was approved by the Institutional Review Board of Yeungnam University Medical Center (approval number: 2018-07-040). The Internal Review Board exempted it from obtaining informed consent from the patients.

Cases and controls
------------------

A case was defined as a patient who underwent high ligation of the IMA (high group, HG). A control was defined as a patient who underwent low ligation of the IMA with additional LN retrieval (low group with additional LN retrieval, LGAL). Controls were identified by matching patients based on age (±5 years), sex, tumor location, and final histopathological tumor stage. Therefore, one control individually matched for age, sex, tumor location, and final histopathological stage was selected per case. Finally, each group included 97 patients.

IMA ligation and additional LN retrieval
----------------------------------------

All operations were performed by 2 senior surgeons. Laparoscopic resection was performed using a standard medial-to-lateral approach. Dissection was performed using a no-touch isolation technique with early dissection of vessels. Mobilization of the splenic flexure was performed if needed. Rectal surgery included partial or total removal of the mesorectum circumferentially with preservation of the hypogastric nerve and the pelvic plexus. Open resection was performed based on standard surgical procedures. Pre- and postoperative procedures were similar for open and laparoscopic resections.

The inferior mesenteric LNs are located around the origin of the IMA. High ligation was defined as ligation of the IMA at its root with LN removal. Low ligation was defined as ligation of the IMA below the origin of the left colic artery. All patients undergoing low ligation underwent additional LN retrieval, which was defined as removal of LN between the root of the IMA and ligation of the IMA.

Adjuvant therapy
----------------

Some patients with rectal cancer received preoperative chemoradiotherapy. The patients presented with clinically T3 or T4 disease or positive nodes. The extent of tumor was evaluated by endorectal ultrasonography or magnetic resonance imaging. Patients received conventional schemes of 40 to 50 Gy delivered over 4 to 5 weeks. Some patients received fluorouracil (FU) and leucovorin (LV) during the first and fifth weeks of pelvic radiotherapy. Others received capecitabine during pelvic radiotherapy. Patients underwent surgery 6 to 8 weeks after preoperative chemoradiotherapy.

Patients with pathologic stage III disease received adjuvant chemotherapy with the FOLFOX regimen (oxaliplatin, FU, LV) or capecitabine. Some patients with pathologic T3 or T4 rectal cancer or positive nodes underwent postoperative chemoradiotherapy based on the same preoperative chemoradiotherapy schedule.

Follow-up
---------

Short-term outcome after curative resection was 30-day postoperative complications. Anastomotic leakage was defined as a defect (demonstrated using a contrast study or computed tomography \[CT\]) in the intestinal wall integrity at the anastomotic site regardless of clinical symptoms. Intestinal obstruction was diagnosed based on signs, symptoms, and radiographic evidence of small bowel obstruction or in those with evidence of impairment in gastrointestinal motility. All patients were followed-up with clinical examination, assessment of tumor markers, colonoscopy, and abdominopelvic and chest CT. All patients underwent a follow-up study every 3 months for the first 2 years and every 6 months thereafter for the next 3 years. If necessary, positron emission tomography was performed to assess recurrence or metastases. Disease-free survival (DFS) was defined as the period without disease including relapse, recurrence, or a second primary cancer including non-colorectal cancers and death due to any cause \[[@b12-ac-2018-10-09]\].

Statistics
----------

All statistical analyses were performed using IBM SPSS Statistics ver. 22.0 (IBM Co., Armonk, NY, USA) and R ver. 3.5 (<http://web-r.org>). Clinicopathological characteristics, postoperative complications, and recurrence were compared using the Pearson chi-square test or Fisher exact test. Operation time, age, and harvested LN were analyzed using Student t-test. DFS and overall survival (OS) rates were analyzed using Kaplan-Meier survival analysis with the log-rank test. P-values \<0.05 were considered statistically significant.

RESULTS
=======

The characteristics of the 194 patients are shown in [Table 1](#t1-ac-2018-10-09){ref-type="table"}. There were no significant differences between the 2 groups. The mean follow-up time was 42.6 ± 18.6 months in HG and 37.2 ± 21.1 months in LGAL (P = 0.063).

Results of harvested LN are shown in [Table 2](#t2-ac-2018-10-09){ref-type="table"}. The pathologic node stage was not different between the 2 groups (P = 0.495). The mean number of the total harvested LNs in all patients was 20.6 ± 11.4. The mean number of total harvested LN was 20.9 ± 13.2 in the HG and 20.2 ± 9.2 in the LGAL (P = 0.673). The mean number of total metastatic LNs was 1.45 (range, 0--30) in total patients, 1.75 (range, 0--30) in the HG, and 1.15 (range, 0--12) in the LGAL (P = 0.247). The mean number of additional harvested LN was 2.19 (range, 0--11) in the LGAL, and one patient had a metastatic LN among the additional harvested LN in this group.

The morbidity rates in the groups are shown in [Table 3](#t3-ac-2018-10-09){ref-type="table"}. The overall morbidity was 22.7% in the HG and 30.9% in the LGAL (P = 0.257). Anastomotic leakage occurred in 14 patients (14.4%) in the HG and 5 patients (5.2%) in the LGAL (P = 0.030). Obstruction and ileus were more common in the LGAL than in the HG (P = 0.013) and occurred in 2 patients (2.1%) in the HG and 12 patients (12.4%) in the LGAL. Most patients with obstruction were managed conservatively including nasogastric tube insertion and nothing pre ora (NPO). However, 1 patient in the LGAL underwent reoperation due to intestinal obstruction. Overall, 8 patients developed infection including pneumonia, catheter infection, or Clostridium colitis.

Of the 194 patients studied, 32 (16.5%) showed metastases ([Table 4](#t4-ac-2018-10-09){ref-type="table"}). Recurrence was noted in 12 patients (12.4%) in the HG and 20 patients (20.6%) in the LGAL (P = 0.122). Systemic metastases occurred in 11 patients (11.3%) in the HG and 18 patients (18.6%) in the LGAL (P = 0.159). In the HG patients with metastases, 2 had only liver metastasis, 5 had only lung metastasis, 1 had liver and lung metastases, and 4 had metastasis to other organs. In the LGAL patients with metastases, 4 had only liver metastasis, 8 had only lung metastasis, 1 had liver and lung metastases, and 7 had metastasis to other organs.

The overall mean DFS time in all participants was 53.9 ± 1.8 months. The mean DFS time was 57.7 ± 2.1 months in the HG and 45.9 ± 2.4 months in the LGAL (P = 0.008) ([Fig. 1](#f1-ac-2018-10-09){ref-type="fig"}). The OS rates are shown in [Fig. 2](#f2-ac-2018-10-09){ref-type="fig"}. The mean OS time in all participants was 70.4 ± 1.3 months. The mean OS time was 63.7 ± 1.6 months in the HG and 69.1 ± 2.6 months in the LGAL (P = 0.386) ([Fig. 2](#f2-ac-2018-10-09){ref-type="fig"}).

DISCUSSION
==========

This study showed that the mean number of LNs in the LGAL was not lower than that in the HG. One patient in the LGAL had a metastatic LN among the additional LN retrieved. Postoperatively, there were no significant differences in morbidity between the 2 groups. However, anastomotic leakage was more frequent in the HG than in the LGAL. No significant intergroup difference was observed in recurrence or OS rate. However, the DFS in the LGAL was lower than that in the HG.

An adequate number of LNs need to be retrieved for curative treatment of colorectal cancer \[[@b13-ac-2018-10-09]\]. Several studies have reported that inadequate LN retrieval was related to poor survival in patients with colorectal cancer \[[@b14-ac-2018-10-09], [@b15-ac-2018-10-09]\] and have recommended that at least 12 LNs be retrieved from a colorectal specimen \[[@b14-ac-2018-10-09]-[@b16-ac-2018-10-09]\]. Both groups in this study had retrieval \>12 LNs. Previous studies have reported that the mean number of harvested LNs between the origin of the IMA and the root of the left colic artery was approximately 2--3 \[[@b3-ac-2018-10-09]\], and the mean number of metastatic LNs between the origin of the IMA and the root of the left colic artery was approximately 1.9--3 \[[@b3-ac-2018-10-09], [@b17-ac-2018-10-09]\]. The tumor invasion rate of apical LNs was reported to be 1.7%--5.8% \[[@b3-ac-2018-10-09], [@b18-ac-2018-10-09]\]. In this study, the number of total harvested LN at the origin of the IMA concurred with other studies, and the tumor invasion rate of apical LN was 1.0%.

The relationship between level of ligation of the IMA and morbidity rate remains controversial. Most studies have shown similar overall complication rates between patients undergoing high and low ligation of the IMA \[[@b17-ac-2018-10-09], [@b19-ac-2018-10-09]\]. Reportedly, overall morbidity rates were approximately 19%--28% in the high and 17%--30% in the low ligation groups \[[@b17-ac-2018-10-09], [@b19-ac-2018-10-09]\]. In this study, the overall morbidity rate was 22%--30%. However, morbidity rates vary based on the kinds of complications. A few studies have demonstrated that high ligation was related to more frequent anastomotic leakage \[[@b20-ac-2018-10-09]-[@b22-ac-2018-10-09]\]. In one study, the anastomotic leakage rate was over 13% in patients undergoing left colic artery non-preservation surgery for rectal cancer \[[@b20-ac-2018-10-09]\]. A few other studies have shown similar rates of anastomotic leakage between patients undergoing high and low ligation of the IMA \[[@b4-ac-2018-10-09], [@b19-ac-2018-10-09]\]. Anastomotic leakage was approximately 7%--10% for all cases of IMA ligation \[[@b4-ac-2018-10-09], [@b19-ac-2018-10-09]\]. The overall anastomotic leakage rate was 9.3% in this study, and anastomotic leakage in the HG was significantly higher than that in the LGAL. We hypothesized that low ligation might affect anastomosis. Previous studies have shown that low ligation of the IMA is associated with better preservation of genitourinary function \[[@b19-ac-2018-10-09]\]. However, ileus and defecation were not improved in those undergoing low ligation of the IMA \[[@b23-ac-2018-10-09]\]. In this study, obstruction was more frequent in the LGAL than the HG. All but one patient was able to be managed conservatively. We suspect that low ligation of the IMA with additional LN retrieval resulted in a larger area without peritoneal coverage near the origin of the IMA, which may have adversely affected gastrointestinal motility.

The relationship between level of IMA ligation and survival remains controversial. High ligation of the IMA aids in LN dissection at its origin. Long-term survival in patients with metastatic LN at the origin of the IMA was poorer than that in patients without metastatic LN at that location, although other studies found that survival rates did not significantly differ based on level of IMA ligation \[[@b1-ac-2018-10-09], [@b17-ac-2018-10-09], [@b24-ac-2018-10-09]\]. Previous studies reported that the five-year OS rate is 82.4%--91.3% and 80.3%--90.2% in the high and low ligation groups, respectively \[[@b17-ac-2018-10-09], [@b24-ac-2018-10-09]\], in which the DFS rate was 75.6%--83.2% and 76.2%--78.0%. In this study, the OS rate did not differ between groups, and the DFS rate in the LGAL was lower than that in the HG.

Limitations of this study are that it was a non-randomized trial and selection biases cannot be ignored. We used case-control matching to overcome the drawbacks associated with the retrospective study design. The follow-up period was longer in the HG than that in the LGAL, although this difference was not statistically significant. High ligation is a conventional procedure that has been performed for a long time in clinical settings. Low ligation with additional LN retrieval is a relatively new technique, and this may be the reason for the shorter follow-up in this group.

No significant intergroup differences were observed in OS or recurrence rate. Anastomotic leakage and DFS were lower in the LGAL. Low ligation of the IMA with additional LN retrieval might be a safe procedure in the surgical management of patients with colorectal cancer. However, oncologic benefits were greater with high ligation of the IMA. Sufficiently powered studies are warranted in the future to provide a better understanding of the differences in clinical outcomes associated with these procedures.

No potential conflict of interest relevant to this article was reported.
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###### 

Clinicopathologic characteristics

  Characteristic                   HG (n = 97)       LGAL (n = 97)      P-value
  -------------------------------- ----------------- ------------------ ---------
  Sex                                                                   1.000
   Female                          31 (32.0)         31 (32.0)          
   Male                            66 (68.0)         66 (68.0)          
  Age (yr)                         64.9 ± 9.7        65.1 ± 9.4         0.898
  Preoperative CEA                 3.2 (0.6--50.8)   3.8 (0.5--287.5)   0.114
  ASA PS classification                                                 0.695
   I--II                           83 (85.6)         80 (82.5)          
   III--IV                         14 (14.4)         17 (17.5)          
  Tumor location                                                        1.000
   Rectum                          45 (46.4)         45 (46.4)          
   Sigmoid                         52 (53.6)         52 (53.6)          
  Preoperative chemoradiotherapy                                        0.566
   No                              89 (91.8)         92 (94.8)          
   Yes                             8 (8.2)           5 (5.2)            
  Operation                                                             0.086
   Laparoscopic                    81 (83.5)         77 (79.4)          
   Open                            11 (11.3)         19 (19.6)          
   Robot                           5 (5.2)           1 (1.0)            
  Operation time (min)             185.3 ± 58.1      170.8 ± 51.4       0.067
  Cell differentiation                                                  0.083
   WD                              10 (10.3)         16 (16.5)          
   MD                              79 (81.4)         79 (81.4)          
   PD/MU/SRC                       8 (8.2)           2 (2.1)            
  Lymphatic invasion                                                    0.593
   No                              64 (66.0)         62 (63.9)          
   Yes                             33 (34.0)         34 (35.1)          
   Indeterminate                   0 (0)             1 (1.0)            
  Vascular invasion                                                     0.591
   No                              87 (89.7)         87 (89.7)          
   Yes                             10 (10.3)         9 (9.3)            
   Indeterminate                   0 (0)             1 (1.0)            
  Neural invasion                                                       0.827
   No                              64 (66.0)         62 (63.9)          
   Yes                             32 (33.0)         33 (34.0)          
   Indeterminate                   1 (1.0)           2 (2.1)            
  Postoperative radiotherapy                                            0.368
   No                              96 (99.0)         93 (95.9)          
   Yes                             1 (1.0)           4 (4.1)            
  Adjuvant chemotherapy                                                 0.886
   No                              47 (48.5)         48 (49.5)          
   Yes                             50 (51.5)         49 (50.5)          
  Pathologic stage                                                      1.000
   I                               23 (23.7)         23 (23.7)          
   IIA                             32 (33.0)         32 (33.0)          
   IIB                             1 (1.0)           1 (1.0)            
   IIIA                            5 (5.2)           5 (5.2)            
   IIIB                            30 (30.9)         30 (30.9)          
   IIIC                            6 (6.2)           6 (6.2)            

Values are presented as number (%), mean ± standard deviation, and median (range).

HG, high group; LGAL, low group with additional lymph node retrieval; CEA, carcinoembryonic antigen; ASA PS, American Society of Anesthesiologists physical status; WD, well differentiated; MD, moderate differentiated; PD, poorly differentiated; MU, mucinous; SRC, signet ring cell.

Age, preoperative CEA and operation time were analyzed using the Student's t-test. The others were analyzed by chi-square test.

###### 

Pathologic results of LNs

  Pathologic result             HG (n = 97)    LGAL (n = 97)   P-value
  ----------------------------- -------------- --------------- ---------
  N stage                                                      0.495
   0                            56 (57.7)      56 (57.7)       
   1a                           18 (18.6)      17 (17.5)       
   1b                           14 (14.4)      12 (12.4)       
   1c                           0 (0)          1 (1.0)         
   2a                           4 (4.1)        9 (9.3)         
   2b                           5 (5.2)        2 (2.1)         
  Total harvested LNs           20.9 ± 13.2    20.2 ± 9.2      0.673
  Total metastatic LNs          1.75 (0--30)   1.15 (0--12)    0.247
  Total harvested LNs of IMA    \-             2.19 (0--11)    \-
  Total metastatic LNs of IMA   \-             0.01 (0--1)     \-

Values are presented as number (%), mean ± standard deviation, or mean (range).

HG, high group; LGAL, low group with additional LN retrieval; LN, lymph node; IMA, inferior mesenteric artery.

N stage was analyzed by chi-square test. Total harvested LNs and total metastatic LNs were analyzed using the Student's t-test.

###### 

Morbidity between the 2 groups

  Morbidity             HG (n = 97)   LGAL (n = 97)   P-value
  --------------------- ------------- --------------- ---------
  Overall morbidity                                   0.257
   No                   75 (77.3)     67 (69.1)       
   Yes                  22 (22.7)     30 (30.9)       
  Anastomotic leakage                                 0.030
   No                   83 (85.6)     92 (94.8)       
   Yes                  14 (14.4)     5 (5.2)         
  Wound                                               0.213
   No                   96 (99.0)     92 (94.8)       
   Yes                  1 (1.0)       5 (5.2)         
  Infection                                           0.071
   No                   96 (99.0)     90 (92.8)       
   Yes                  1 (1.0)       7 (7.2)         
  Obstruction                                         0.013
   No                   95 (97.9)     85 (87.6)       
   Yes                  2 (2.1)       12 (12.4)       
  Others                                              1.000
   No                   96 (99.0)     95 (97.9)       
   Yes                  1 (1.0)       2 (2.1)         

Values are presented as number (%).

HG, high group; LGAL, low group with additional lymph node retrieval.

All values were analyzed by chi-square test.

###### 

Recurrence between the 2 groups

  Recurrence            HG (n = 97)   LGAL (n = 97)   P-value
  --------------------- ------------- --------------- ---------
  Total recurrence                                    0.122
   No                   85 (87.6)     77 (79.4)       
   Yes                  12 (12.4)     20 (20.6)       
  Systemic metastasis                                 0.159
   No                   86 (88.7)     79 (81.4)       
   Yes                  11 (11.3)     18 (18.6)       
  Local recurrence                                    0.621
   No                   96 (99.0)     94 (96.9)       
   Yes                  1 (1.0)       3 (3.1)         

Values are presented as number (%).

HG, high group; LGAL, low group with additional lymph node retrieval.

All values were analyzed by chi-square test.
